Tumor Suppressor Proteins
"Tumor Suppressor Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.
| Descriptor ID |
D025521
|
| MeSH Number(s) |
D12.776.624.776
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tumor Suppressor Proteins".
Below are MeSH descriptors whose meaning is more specific than "Tumor Suppressor Proteins".
This graph shows the total number of publications written about "Tumor Suppressor Proteins" by people in this website by year, and whether "Tumor Suppressor Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 3 | 1 | 4 |
| 1999 | 6 | 0 | 6 |
| 2000 | 4 | 1 | 5 |
| 2001 | 3 | 4 | 7 |
| 2002 | 2 | 13 | 15 |
| 2003 | 6 | 10 | 16 |
| 2004 | 2 | 15 | 17 |
| 2005 | 8 | 7 | 15 |
| 2006 | 7 | 4 | 11 |
| 2007 | 12 | 15 | 27 |
| 2008 | 9 | 4 | 13 |
| 2009 | 7 | 5 | 12 |
| 2010 | 12 | 10 | 22 |
| 2011 | 9 | 3 | 12 |
| 2012 | 9 | 11 | 20 |
| 2013 | 12 | 6 | 18 |
| 2014 | 8 | 5 | 13 |
| 2015 | 5 | 9 | 14 |
| 2016 | 7 | 4 | 11 |
| 2017 | 5 | 5 | 10 |
| 2018 | 6 | 5 | 11 |
| 2019 | 9 | 6 | 15 |
| 2020 | 6 | 6 | 12 |
| 2021 | 3 | 5 | 8 |
| 2022 | 2 | 6 | 8 |
| 2023 | 1 | 4 | 5 |
| 2024 | 1 | 3 | 4 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tumor Suppressor Proteins" by people in Profiles.
-
Longitudinal multimodal profiling of IDH-wildtype glioblastoma reveals the molecular evolution and cellular phenotypes underlying prognostically different treatment responses. Neuro Oncol. 2025 Jan 12; 27(1):89-105.
-
DNA-binding affinity and specificity determine the phenotypic diversity in BCL11B-related disorders. Am J Hum Genet. 2025 Feb 06; 112(2):394-413.
-
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial. JAMA Oncol. 2024 Dec 01; 10(12):1637-1644.
-
WWOX tuning of oleic acid signaling orchestrates immunosuppressive macrophage polarization and sensitizes hepatocellular carcinoma to immunotherapy. J Immunother Cancer. 2024 Nov 05; 12(11).
-
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 10 23; 14(1):168.
-
Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimers Dement. 2024 Dec; 20(12):8470-8483.
-
Analysis of DNA Methylation in Gliomas: Assessment of Preanalytical Variables. Lab Invest. 2024 Dec; 104(12):102160.
-
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
-
Temozolomide use in elderly patients with MGMT promoter unmethylated glioblastoma: Is it finally time to dismount a dead horse? Neuro Oncol. 2024 Oct 03; 26(10):1876-1877.
-
Prognostic Impact of Notch1 Intracellular Domain, P63, and c-MYC in Lacrimal Gland Adenoid Cystic Carcinoma. Invest Ophthalmol Vis Sci. 2024 Sep 03; 65(11):4.